Literature DB >> 18801310

A study of intestinal absorption of bicyclol in rats: active efflux transport and metabolism as causes of its poor bioavailability.

Wei Tan1, Hui Chen, Jing Zhao, Jinping Hu, Yan Li.   

Abstract

PURPOSE: To determine the possible mechanism of poor bioavailability of bicyclol, and clarify the respective contribution of P- glycoprotein (P-gp) and Cytochrome 3A (CYP3A).
METHODS: Rat in situ single-pass intestinal perfusion and Caco-2 cell monolayer model with selective inhibitors of CYP3A and P-gp were employed.
RESULTS: In rat intestinal perfusion, bicyclol (50 microM) appearance in mesenteric blood (Pblood) was increased 3, 12 and 16-fold after addition of inhibitors of P-gp (LSN335984), CYP3A (troleandomycin, TAO) or P-gp and CYP3A (Cyclosporin A, CsA), respectively, whereas permeability of midazolam (CYP3A substrate only) was unchanged after addition of LSN335984 and increased 5 fold after addition of TAO. Moreover, the cumulative amount of bicyclol in mesenteric blood was increased at concentration range 10-100 microM of bicyclol in perfusate. The basolateral to apical permeability value of bicyclol in Caco-2 monolayer was significantly deceased by LSN335984 and CsA.
CONCLUSIONS: The poor bioavailability of bicyclol is mostly due to P-gp mediated efflux and metabolism by CYP3A in intestine, with CYP3A making more contribution than P-gp.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18801310     DOI: 10.18433/j3b88v

Source DB:  PubMed          Journal:  J Pharm Pharm Sci        ISSN: 1482-1826            Impact factor:   2.327


  1 in total

1.  Pharmacokinetic optimization of 4-substituted methoxybenzoyl-aryl-thiazole and 2-aryl-4-benzoyl-imidazole for improving oral bioavailability.

Authors:  Chien-Ming Li; Jianjun Chen; Yan Lu; Ramesh Narayanan; Deanna N Parke; Wei Li; Sunjoo Ahn; Duane D Miller; James T Dalton
Journal:  Drug Metab Dispos       Date:  2011-07-08       Impact factor: 3.922

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.